Trial Information
Inclusion Criteria
- Diagnosis of relapsed or refractory low-grade, CD20+, B-cell NHL * Received and
failed at least 1 prior regimen of chemotherapy * Rituximab-naive or received prior
rituximab in their last treatment (single agent or in combination with chemotherapy)
and demonstrated a time to progression of at least 12 months.
Type of Study:
Interventional
Study Design:
Primary Purpose: Treatment
Principal Investigator
MD
Investigator Role:
Study Director
Investigator Affiliation:
Amgen
Authority:
United States: Food and Drug Administration
Study ID:
20010138
NCT ID:
NCT00044902
Start Date:
Completion Date:
Related Keywords:
- Non-Hodgkin's Lymphoma
- Lymphoma
- Lymphoma, Non-Hodgkin